Related Experiment Videos
An overview of intermittent inotropic therapy for severe congestive heart failure
A W Friedman1, S J Silver, R A Minella
1Shadyside Hospital and the University of Pittsburgh Medical Center, Pittsburgh, PA 15206.
Insights
Intermittent inotropic therapy shows promise for congestive heart failure (CHF) patients, with most studies reporting benefits. However, larger, controlled trials are needed to confirm its safety and effectiveness.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Congestive heart failure (CHF) affects over 4 million Americans, causing significant morbidity and healthcare costs.
- Limited treatment options exist for elderly patients with resistant CHF on maximal medical therapy.
- Intermittent inotropic therapy is a debated treatment approach for advanced heart failure.
Purpose of the Study:
- To review existing literature on intermittent inotropic therapy for congestive heart failure.
- To evaluate the reported benefits and limitations of this therapeutic approach.
Main Methods:
- Systematic review of 20 studies on intermittent inotropic therapy.
- Analysis of study designs, reported outcomes, and criticisms.
Main Results:
- Nineteen out of 20 reviewed studies indicated beneficial effects of intermittent inotropic therapy.
- Major criticisms include small sample sizes and lack of randomization and placebo controls in existing studies.
Conclusions:
- Intermittent inotropic therapy may offer benefits for select CHF patients.
- Larger, well-controlled studies are essential to establish the efficacy and safety of this treatment.
- Fair evaluation of all therapies is crucial to reduce hospitalizations, mortality, and improve quality of life in CHF patients.
Abstract:
Congestive heart failure (CHF) is a major problem in the field of medicine in the U.S. Over 4 million people in the U.S. have CHF with 400,000 new cases per year. This diagnosis creates 6 million hospital days with a Medicare cost of billions of dollars. There are limited options for patients >65 years of age who have resistant heart failure on maximum medical therapy. There is considerable debate surrounding intermittent inotropic therapy. This paper is a review of the literature regarding this form of therapy; 20 studies are described. All but one of these studies disclose beneficial effects. The major criticism of these studies is that they are small and not randomized or placebo controlled. Larger well controlled studies are needed to determine the effect and safety of this treatment. Researchers must develop and evaluate all forms of therapy fairly to help decrease hospitalizations, decrease mortality, and improve quality of life.